|
市場調査レポート
癌診断における技術革新：技術進歩、成長機会、将来の市場見通し
Innovations in Oncology Diagnostics: Technological advances, growth opportunities and future market outlook
|
Abstract
Despite public policy measures to prevent cancer, such as tobacco control and
vaccination against HPV, cancer is sure to remain a significant public health
problem throughout the 21st century. Indeed, the global demographic shift
towards an ageing population and the spread of high tech modern medicine
throughout the emerging economies of Asia and (maybe later) Africa, will
expand the market for cancer diagnostics globally. Major developments are
likely in both the IVD market and in imaging-based modalities, like computed
tomography, with the emphasis being upon the personalized medicine approach,
where demand will come from physicians, patients and payors - all of whom
want more effective treatments and value for money. ' Innovations in Oncology
Diagnostics' is a new report published by Business Insights that analyzes the
latest innovations in oncology diagnostics and identifies the most exciting
new technologies and trends, ranging from body imaging and cytology to
molecular diagnostics and pharmacogenomics. This report also identifies the
key challenges facing innovative diagnostics companies.
Table of Contents
Executive summary
- Setting the scene
- Innovations in diagnostic imaging
- Innovations in molecular diagnostics
- Innovations in pharmacogenomics
- Challenges in the oncology diagnostics sector
- Competitive landscape
Chapter 1 Setting the scene
- Summary
- Introduction
- Cancer facts, current and projected
- History of oncology diagnostics
- Elements of a cancer diagnosis
- Pathology
- Oncology diagnostics market
Chapter 2 Innovations in diagnostic imaging
- Summary
- Introduction
- Body imaging
- Overview
- X-ray
- Computed tomography
- Lung cancer
- Colon cancer
- Others
- Ultrasound
- Magnetic resonance imaging
- Nuclear medicine - PET & SPECT
- Case study
- Cytology
- Overview
- Flow cytometry
- Case study
- Cervical screening
- Cytogenetics
Chapter 3 Innovations in molecular diagnostics
- Summary
- Introduction
- DNA, genes and chromosomes
- Fluorescence in situ hybridization (FISH)
- PCR and variants
- Case study
- Immunoassays and biomarkers
- Case study
- Ovarian cancer
- PSA testing
- Other areas of research
- Epigenomics
- Microarrays
- Comparative genomic hybridization (CGH)
- Case study
- Overview of clinical applications of molecular diagnostics
Chapter 4 Innovations in pharmacogenomics
- Summary
- Introduction
- Familial cancer
- Breast cancer
- Colon cancer
- Melanoma
- Case study
- Response to therapy
- Cytochrome P450 variants
- HER2 overexpression
- The FDA, EMEA and PGx labeling
- Case study
- TheraScreen: KRAS
- BioTheranostics: Breast cancer
- Clarient: Breast cancer
- Marker validation for erlotinib in lung cancer
- Companion diagnostics
Chapter 5 Challenges in the oncology diagnostics sector
- Summary
- Introduction
- Reimbursement funding
- Educated patients = educated decisions
- Regulation
- Pharmacoeconomics
- Emerging markets
- Partnerships between drug companies & academia
- Research & development
- Mergers & acquisitions
Chapter 6 Competitive landscape
- Summary
- Introduction
- Abbot Diagnostics
- Affymetrix
- Beckman Coulter
- Becton Dickinson
- Bio-Rad Laboratories
- Gen-Probe
- Johnson & Johnson (J&J)
- Ortho Clinical Diagnostics
- Luminex
- Nanogen
- Roche Diagnostics
- Siemens Healthcare Diagnostics
- Sysmex
- Future perspectives in the oncology diagnostics market
- Science
- Infrastructure
- Adoption of innovation
- Companion diagnostics
Chapter 7 Appendix
List of Figures
- Figure 1.1: Leading sites of new cancer US, 2009
- Figure 1.2: Leading sites of new cancer in developing countries, 2007
- Figure 1.3: Information required by oncologist pre/post diagnosis
- Figure 1.4: Oncology diagnostics forecasts ($bn), 2007-14
- Figure 2.5: Example of the use of 3D tomosynthesis imaging
- Figure 2.6: Number of CT scans in the US, 1995-2008
- Figure 2.7: Women having mammograms (%) in the US, 2004*
- Figure 2.8: Global flow cytometry market forecast ($bn), 2008-14
- Figure 3.9: IV diagnostics market forecast ($bn), 2007-2014)
- Figure 3.10: Use of biomarkers
- Figure 3.11: Obstacles to biomarker development
- Figure 3.12: US 5-year survival (%) for ovarian cancer at time of diagnosis
- Figure 4.13: Myriad: Molecular diagnostics sales ($m), 2005-09
- Figure 4.14: Number of biologics regulated by CDER that have existing PGx
information
- Figure 4.15: Herceptin therapy cost ($) per patient relative to HER2
testing
- Figure 5.16: Decline in S&P global sector indices (%), 12 months to
December 2008
- Figure 5.17: IV diagnostics risk-based classification
- Figure 5.18: FDA validated biomarkers by therapeutic area, September 2009
- Figure 5.19: Roche Diagnostics regional sales (CHFm), 2008
- Figure 5.20: Leading diagnostic firms increase in R&D spend (%) y-o-y, 2008
List of Tables
- Table 1.1: WHO cancer mortality forecasts by region (' 000), 2008-30
- Table 1.2: In vitro diagnostics market forecast ($bn), 2008-14
- Table 2.3: Overview of imaging systems
- Table 2.4: Mortality reduction (%) attributed to FOBT screening, 1985-96
- Table 2.5: Organ radiation data from various clinical studies
- Table 3.6: Extensively investigated cancer biomarkers
- Table 3.7: Market potential for Epigenomics' cancer specialty tests
- Table 4.8: Absent/incomplete efficacy (%) of drugs by therapeutic class
- Table 5.9: Leading M&A deals in the diagnostics industry ($m), 2009
- Table 6.10: Sales for the leading innovative oncology diagnostics
companies ($m), 2006-08
- Table 6.11: Beckman Coulter R&D investment ($m), 2004-08
- Table 6.12: Bio-Rad sales ($bn) 2004-2008
- Table 6.13: Roche Diagnostics sales by division (CHFm), H109
- Table 6.14: Major recent Dx-Rx partnerships
|
